NeOnc Technologies Wins Abu Dhabi Approval for Phase 2 Brain Cancer Trial

Key Facts

In a move reflecting the UAE's growing ambitions to become a global hub for biotech innovation, the Department of Health – Abu Dhabi has cleared NeOnc Technologies to begin Phase 2 clinical trials. The company’s NEO212 drug, targeting brain tumors, was granted Investigational New Drug (IND) status by the regulator. This approval follows the successful completion of Phase 1 dose escalation studies, which established 610 mg as the recommended dosage for the upcoming Phase 2 trials.

This regulatory milestone positions NeOnc to expand its clinical pathway internationally while it maintains ongoing discussions with the U.S. FDA regarding a potential registrational pathway. Compared to other oncology-focused biotech firms, expanding into Gulf markets offers streamlined access to sophisticated regulatory environments, per market data. These developments coincide with significant investments in Abu Dhabi’s healthcare sector aimed at fostering advanced clinical research and specialized treatments.

Regarding market performance, NTHI shares closed at $4.51 (close June 15, 2026), trading within a range of $4.30 to $4.82 during the session. Investors should watch for the commencement of patient enrollment in Abu Dhabi as the next primary catalyst for the stock. Additionally, broader market sentiment may be influenced by upcoming global events, including the European Central Bank's interest rate decision scheduled for June 11, which impacts risk appetite for growth-stage companies.